Immunovia on Monday said the U.S. Department of Health and Human Services’ Centers for Medicare and Medicaid Services (CMS) has issued a preliminary payment determination for the firm’s Immray PanCan-d test.
The CMS preliminary payment determination implied a test price of $897.
The price determination agrees with a recommendation by the Clinical Diagnostic Laboratory Tests (CDLT) Advisory Panel to crosswalk the Immray PanCan-d rate to code 81503, brand name OVA1, which currently has a price of $897, Immunovia said.
"While this does not represent a coverage determination to reimburse the Immray PanCan-d test,
it is an important step in the process of securing reimbursement for the Immray PanCan-d test in the early detection of pancreatic cancer," Philipp Mathieu, CEO and president of Immunovia, said in a statement.
Immray PanCan-d is a blood test launched as a laboratory-developed test in August 2021 for the early detection of pancreatic cancer.
The Lund, Sweden-based company said it expects CMS to finalize its basis for the payment decision in November.
